Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C15H16N3S |
| Molecular Weight | 270.373 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 1 |
SHOW SMILES / InChI
SMILES
CN(C)C1=CC2=[S+]C3=CC(N)=C(C)C=C3N=C2C=C1
InChI
InChIKey=RQNADZJRELIICT-UHFFFAOYSA-N
InChI=1S/C15H16N3S/c1-9-6-13-15(8-11(9)16)19-14-7-10(18(2)3)4-5-12(14)17-13/h4-8H,16H2,1-3H3/q+1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/22923899
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923899
Tolonium chloride (INN, also known as toluidine blue or TBO) is a phenothiazine that has been used as a hemostatic, a biological stain, and a dye for wool and silk. Tolonium chloride has also been used as a diagnostic aid for oral and gastric neoplasms and in the identification of the parathyroid gland in thyroid surgery. Toluidine blue has high affinity for acidic tissue components, thereby staining tissues rich in DNA and RNA. It has found wide applications both as vital staining in living tissues and as a special stain owing to its metachromatic property. Toluidine blue has been used in vivo to identify dysplasia and carcinoma of the oral cavity.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923899
Curator's Comment: William Henry Perkin in 1856
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: DNA or RNA Sources: https://www.ncbi.nlm.nih.gov/pubmed/22923899 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Blutene Approved UseTreatment and prevention of excessive menstrual flow. |
|||
| Diagnostic | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
|||
| Diagnostic | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
2 mg/kg 1 times / day single, intravenous Studied dose Dose: 2 mg/kg, 1 times / day Route: intravenous Route: single Dose: 2 mg/kg, 1 times / day Sources: |
unhealthy, 27 years |
Other AEs: Edema... |
4 mg/kg 1 times / day single, intravenous Studied dose Dose: 4 mg/kg, 1 times / day Route: intravenous Route: single Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy, adult |
Other AEs: Cardiac arrhythmia... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Edema | 2 mg/kg 1 times / day single, intravenous Studied dose Dose: 2 mg/kg, 1 times / day Route: intravenous Route: single Dose: 2 mg/kg, 1 times / day Sources: |
unhealthy, 27 years |
|
| Cardiac arrhythmia | 4 mg/kg 1 times / day single, intravenous Studied dose Dose: 4 mg/kg, 1 times / day Route: intravenous Route: single Dose: 4 mg/kg, 1 times / day Sources: |
unhealthy, adult |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01330082
Examination of the oral cavity after the local application of Toluidine Blue dye (tolonium chloride)
Route of Administration:
Other
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
P3Y6XJA2D1
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
PRIMARY | |||
|
46992-32-9
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
SUPERSEDED | |||
|
7084
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
PRIMARY | |||
|
1442649-22-0
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
SUPERSEDED | |||
|
1335281-20-3
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
SUPERSEDED | |||
|
1258839-02-9
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
SUPERSEDED | |||
|
430434-33-6
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
SUPERSEDED | |||
|
100000084656
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
PRIMARY | |||
|
2701
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
PRIMARY | |||
|
SUB04911MIG
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
PRIMARY | |||
|
87648
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
PRIMARY | |||
|
56109-24-1
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
PRIMARY | |||
|
99963-91-4
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
SUPERSEDED | |||
|
366-14-3
Created by
admin on Mon Mar 31 22:11:54 GMT 2025 , Edited by admin on Mon Mar 31 22:11:54 GMT 2025
|
SUPERSEDED |
ACTIVE MOIETY